Free Trial
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

Ginkgo Bioworks logo
$7.63
-0.21 (-2.68%)
(As of 10/31/2024 ET)

About Ginkgo Bioworks Stock (NYSE:DNA)

Key Stats

Today's Range
$7.50
$7.82
50-Day Range
$5.37
$9.38
52-Week Range
$5.26
$75.20
Volume
629,940 shs
Average Volume
1.14 million shs
Market Capitalization
$424.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.16
Consensus Rating
Reduce

Company Overview

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

Ginkgo Bioworks Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
17th Percentile Overall Score

DNA MarketRank™: 

Ginkgo Bioworks scored higher than 17% of companies evaluated by MarketBeat, and ranked 936th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ginkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Ginkgo Bioworks has only been the subject of 2 research reports in the past 90 days.

  • Read more about Ginkgo Bioworks' stock forecast and price target.
  • Earnings Growth

    Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($12.60) to ($6.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ginkgo Bioworks is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ginkgo Bioworks is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ginkgo Bioworks has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ginkgo Bioworks' valuation and earnings.
  • Percentage of Shares Shorted

    22.23% of the float of Ginkgo Bioworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Ginkgo Bioworks has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Ginkgo Bioworks has recently decreased by 3.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    Ginkgo Bioworks does not currently pay a dividend.

  • Dividend Growth

    Ginkgo Bioworks does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.23% of the float of Ginkgo Bioworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Ginkgo Bioworks has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Ginkgo Bioworks has recently decreased by 3.79%, indicating that investor sentiment is improving.
  • News Sentiment

    Ginkgo Bioworks has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Ginkgo Bioworks this week, compared to 6 articles on an average week.
  • Search Interest

    Only 13 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -24% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,626.00 in company stock.

  • Percentage Held by Insiders

    Only 9.72% of the stock of Ginkgo Bioworks is held by insiders.

  • Percentage Held by Institutions

    78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ginkgo Bioworks' insider trading history.
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

DNA Stock News Headlines

Ex WH Advisor Who Predicted Biden Leaving Race Makes Startling New Prediction
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
See More Headlines

DNA Stock Analysis - Frequently Asked Questions

Ginkgo Bioworks' stock was trading at $8.2950 at the beginning of the year. Since then, DNA stock has decreased by 8.1% and is now trading at $7.62.
View the best growth stocks for 2024 here
.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its quarterly earnings results on Thursday, August, 8th. The company reported ($3.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($3.20). The company earned $56.21 million during the quarter, compared to analysts' expectations of $41.46 million. Ginkgo Bioworks had a negative net margin of 486.98% and a negative trailing twelve-month return on equity of 63.09%.

Ginkgo Bioworks' top institutional shareholders include Exchange Traded Concepts LLC (0.66%), PFG Investments LLC (0.34%), Forbes J M & Co. LLP (0.22%) and Green Alpha Advisors LLC. Insiders that own company stock include Reshma P Shetty, Barry Canton, Marijn E Dekkers, Jason R Kelly, Christian O Henry, Mark E Dmytruk, Harry Sloan, Marie E Fallon and Steven P Coen.
View institutional ownership trends
.

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB).

Company Calendar

Last Earnings
8/08/2024
Today
10/31/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
1,218
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.16
High Stock Price Target
$10.00
Low Stock Price Target
$0.30
Potential Upside/Downside
-47.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$-892,870,000.00
Net Margins
-486.98%
Pretax Margin
-486.98%

Debt

Sales & Book Value

Annual Sales
$184.34 million
Book Value
$21.93 per share

Miscellaneous

Free Float
50,173,000
Market Cap
$435.99 million
Optionable
Optionable
Beta
1.10
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NYSE:DNA) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners